Scholarlink

Background <p>The second most seen malignancy occurrence among males is prostate cancer. The p90 ribosomal s6 kinase (RSK) has attracted increased attention due to its overexpression in cancer cells, especially prostate cancer cells. Significant progress has been made recently to develop RSK inhibitors to treat prostate cancer, but these efforts have shown limited success.</p> Methods <p>Molecular docking and other computational analysis procedures using the Schrodinger suite were used to predict in silico the ability of bioactive compounds from turmeric (<i>Curcuma longa</i>) to bind effectively to RSK as potent inhibitors. Forty-three (43) selected compounds from turmeric were screened against RSK. After the molecular and induced-fit docking, the hit compounds were later subjected to ADMET, MMGBSA, and QSAR analyses using the Schrödinger suite.</p> Results <p>Five bioactive compounds may be possible lead drugs for the treatment of prostate cancer because they have the lowest binding energies, ranging from −&#xa0;9.0&#xa0;kcal/mol to −&#xa0;11.00&#xa0;kcal/mol, and have better pharmacokinetic qualities than the standard drugs docetaxel, enzalutamide, and abiraterone. The ligand and receptor had induced fit scores of −&#xa0;8.511, −&#xa0;6.977, −&#xa0;8.671, −&#xa0;9.548, and −&#xa0;8.287 for 3-O-caffeoylquinic acid, 8-hydroxyl-ar-turmeron, bisdemethoxycurcumin, Curcumin II, and demethoxycurcumin, respectively. These hit compounds after ADMET prediction do not violate Lipinski's rule of five.</p> Conclusion <p>The work suggested that turmeric phytocompounds are effective RSK inhibitors for prostate cancer treatment. Further in vivo and in vitro investigations can confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The potential of Curcuma longa L. bioactive compounds as RSK inhibitors for the treatment of prostate cancer: in silico study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月28日

查看全文
  • Olusola Olalekan Elekofehinti,
  • Foluso Adeola Taiwo,
  • Moses Orimoloye Akinjiyan,
  • Ifeoluwa Rachael Adetoyi,
  • Folasade Oluwatobiloba Ayodeji,
  • Adedotun Olayemi Oluwatuyi,
  • Oluwapelumi Nifesimi Akintoye,
  • Idayat Oyinkansola Kehinde,
  • Bolanle Esther Adedapo,
  • Opeyemi Iwaloye

摘要

Background

The second most seen malignancy occurrence among males is prostate cancer. The p90 ribosomal s6 kinase (RSK) has attracted increased attention due to its overexpression in cancer cells, especially prostate cancer cells. Significant progress has been made recently to develop RSK inhibitors to treat prostate cancer, but these efforts have shown limited success.

Methods

Molecular docking and other computational analysis procedures using the Schrodinger suite were used to predict in silico the ability of bioactive compounds from turmeric (Curcuma longa) to bind effectively to RSK as potent inhibitors. Forty-three (43) selected compounds from turmeric were screened against RSK. After the molecular and induced-fit docking, the hit compounds were later subjected to ADMET, MMGBSA, and QSAR analyses using the Schrödinger suite.

Results

Five bioactive compounds may be possible lead drugs for the treatment of prostate cancer because they have the lowest binding energies, ranging from − 9.0 kcal/mol to − 11.00 kcal/mol, and have better pharmacokinetic qualities than the standard drugs docetaxel, enzalutamide, and abiraterone. The ligand and receptor had induced fit scores of − 8.511, − 6.977, − 8.671, − 9.548, and − 8.287 for 3-O-caffeoylquinic acid, 8-hydroxyl-ar-turmeron, bisdemethoxycurcumin, Curcumin II, and demethoxycurcumin, respectively. These hit compounds after ADMET prediction do not violate Lipinski's rule of five.

Conclusion

The work suggested that turmeric phytocompounds are effective RSK inhibitors for prostate cancer treatment. Further in vivo and in vitro investigations can confirm these findings.